Overview
- Bristol Myers Squibb, which announced the strategic agreement on Wednesday, May 20, 2026, said it will roll out Anthropic’s Claude across research, clinical development, manufacturing, commercial and corporate teams.
- The company plans a large-scale deployment covering more than 30,000 employees and will use Claude Code to standardize and speed internal software and AI engineering.
- BMS identified three near-term priorities: accelerate engineering with Claude Code, embed agentic AI into drug-moving workflows, and connect Claude to decades of institutional scientific and clinical data.
- Anthropic says Claude can draft clinical study reports from trial data, surface scientific context from internal research, and trace manufacturing deviations in real time, while BMS says integrations will include enterprise governance and audit controls to support regulated use.
- The deal builds on BMS’s three-plus years of AI investment and Anthropic’s recent expansion of compute capacity, and reporting indicates potential use of Tempus’ Lens to analyze de-identified patient records to refine trial design and patient selection.